Results 241 to 250 of about 37,961 (284)
Some of the next articles are maybe not open access.

Albumin transcytosis in mesothelium

American Journal of Physiology-Lung Cellular and Molecular Physiology, 2002
Apparent permeability to albumin ( P alb) was measured with125I-albumin in specimens of rabbit parietal pericardium from lumen to interstitium (L-I) and from interstitium to lumen (I-L). With albumin concentration (Calb) 0.5%, P alb (× 10−5 cm/s) L-I at 37°C was 0.172 ± 0.019 SE; it decreased to 0.092 ± 0.022 I-L at 37°C, 0.089 ± 0.021 L-I at 12°C ...
F. Bodega, L. Zocchi, E. Agostoni
openaire   +3 more sources

Endocytosis and transcytosis

Advanced Drug Delivery Reviews, 1998
Vesicular coat proteins mediate the formation of nascent vesicles and select the cargo to be incorporated therein. As additional coat proteins are discovered that regulate vesicular traffic along very specific intracellular pathways, the possibility looms of regulating the intracellular trafficking and targeting of therapeutic agents by modulation of ...
exaly   +3 more sources

Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies

Pharmaceutics
The blood–brain barrier (BBB) is a highly selective and natural protective membrane that restricts the entry of therapeutic agents into the central nervous system (CNS).
Ling Ding   +3 more
semanticscholar   +1 more source

Transcytosis and Catabolism of Antibody

Immunologic Research, 2002
This review describes the evolution of our knowledge of the transmission of immunoglobulin G (IgG) from mother to infant and the factors which regulate the persistence of IgG in the circulation. These apparently unrelated processes involve the same Fc receptor, FcRn (n = neonatal).
Victor, Ghetie, E Sally, Ward
openaire   +2 more sources

VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis.

Metabolism: Clinical and Experimental, 2022
BACKGROUND Activation of NLRP3 inflammasome accelerates the formation of atherosclerotic plaques. Here, we evaluated the effects of inflammation on the expression of the NLRP3 inflammasome in endothelial cells (ECs).
Xiong Jia   +10 more
semanticscholar   +1 more source

Albumin transcytosis from the pleural space

Journal of Applied Physiology, 2002
Occurrence of transcytosis in pleural mesothelium was verified by measuring removal of labeled macromolecules from pleural liquid in experiments without and with nocodazole. To this end, we injected 0.3 ml of Ringer-albumin with 750 μg of albumin-Texas red or with 600 μg of dextran 70-Texas red in the right pleural space of anesthetized rabbits, and ...
E. Agostoni, F. Bodega, L. Zocchi
openaire   +3 more sources

Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells.

Journal of the American Chemical Society
Targeted protein degradation (TPD) has emerged as an effective therapeutic strategy for a wide range of diseases; however, the blood-brain barrier (BBB) limits access of degraders into the central nervous system (CNS).
Rebecca A Howell   +4 more
semanticscholar   +1 more source

Transcytosis-Based Renal Tubular Reabsorption of Luminescent Gold Nanoparticles for Enhanced Tumor Imaging.

Angewandte Chemie
Transcytosis-based tubular reabsorption of endogenous proteins is a well-known energy-saving pathway that prevents nutrient loss. However, utilization of this well-known reabsorption pathway for the delivery of exogenous nanodrugs remains a challenge. In
Di Huang   +5 more
semanticscholar   +1 more source

Endothelial transcytosis in health and disease

Cell and Tissue Research, 2008
The visionaries predicted the existence of transcytosis in endothelial cells; the cell biologists deciphered its mechanisms and (in part) the molecules involved in the process; the cell pathologists unravelled the presence of defective transcytosis in some diseases.
Maya, Simionescu   +2 more
openaire   +2 more sources

Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.

Biomaterials, 2020
Nanotechnology-based drug delivery platforms have been explored for cancer treatments and resulted in several nanomedicines in clinical uses and many in clinical trials.
Quan Zhou   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy